Barclays
IMMX icon

Barclays’s Immix Biopharma IMMX Stock Holding History

Barclays’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Buy
51,768
+16,768
+48% +$123K ﹤0.01% 3222
2025
Q4 		$183K Buy
+35,000
New +$144K ﹤0.01% 4363

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Barclays's IMMX Position: Q1 2026 in Review

Barclays increased its Immix Biopharma (IMMX) stake by 48% in Q1 2026, buying an estimated $123K and bringing the position to 51,768 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

Barclays first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Barclays held 51,768 shares of Immix Biopharma worth $472K as of Q1 2026.
  • Barclays bought 16,768 Immix Biopharma shares in Q1 2026, an estimated $123K.
  • Immix Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3222 holding.
  • Barclays first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.